Viral vaccine composition, process and methods of use

Details Viral vaccine composition, process and methods of use Viral vaccine composition, process and methods of use

2008-04-14

2010-11-23

Lucas, Zachariah (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S184100, C424S227100, C424S228100, C435S236000

Reexamination Certificate

active

07838006

ABSTRACT:
A composition for treating or preventing virus-induced infections is described, along with a process of producing the composition and methods of the composition's use. The composition comprises viral pathogen-infected cell or tissue, or malignantly or immunologically aberrant cells or tissues which has been reduced and/or denatured. The preferred composition is administered across a mucosal surface of an animal suffering or about suffer from infection. The composition is administered as preventive or therapeutic vaccine.

REFERENCES:
patent: 3060094 (1962-10-01), Dutcher et al.
patent: 3859168 (1975-01-01), Barth et al.
patent: 4568542 (1986-02-01), Kronenberg
patent: 4695454 (1987-09-01), Prince et al.
patent: 5506271 (1996-04-01), Meruelo et al.
patent: 5709995 (1998-01-01), Chisari et al.
patent: 5994083 (1999-11-01), Felici et al.
patent: 6024953 (2000-02-01), Lathe et al.
patent: 6245532 (2001-06-01), Smith et al.
patent: 6383806 (2002-05-01), Rios
patent: 6515028 (2003-02-01), Mueller et al.
patent: 6544528 (2003-04-01), Yamamoto
patent: 6623764 (2003-09-01), Sokoll et al.
patent: 6635246 (2003-10-01), Barrett et al.
patent: 2002/0001595 (2002-01-01), Sonntag et al.
patent: 2003/0143221 (2003-07-01), Loibner et al.
patent: 0775494 (1997-05-01), None
patent: 57175127 (1982-10-01), None
patent: WO-9714434 (1997-04-01), None
patent: WO-0024420 (2000-05-01), None
patent: WO-0047222 (2000-08-01), None
Berzofsky et al., “Progress on new vaccine strategies against chronic viral infections.,” Journal of Clinical Investigation, vol. 114 No. 4, pp. 450-462 (Aug. 2004).
Huang et al., “Recent development of therapeutics for chronic HCV infection,” Antiviral Research, vol. 71 Nos. 2-3, pp. 351-362 (Sep. 2006).
Hughes et al.“Isolation and immunizations with hepatitis A viral structural proteins: induction of antiprotein, antiviral, and neutralizing responses,” Journal of Virology, vol. 55 No. 2, pp. 395-401 (Aug. 1985).
Koziel et al., “Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV,” Journal of Virology, vol. 67 No. 12, pp. 7522-7532 (Dec. 1993).
Prince et al., “Strategies for evaluation of enveloped virus inactivation in red cell concentrates using hypericin,” Photochemistry and photobiology, vol. 71 No. 2, pp. 188-195 (Feb. 2000).
Rascanelli et al., “Presentation of HCV antigens to naive CD8+T cells: why the where, when, what and how are important for virus control and infection outcome,” Clincal Immunology, vol. 124 No. 1, pp. 5-12 (E-pub May 2007).
Rollier et al., “Control of Heterologous Hepatitis C Virus Infection in Chimpanzees Is Associated with the Quality of Vaccine-Induced Peripheral T-Helper Immune Response ,” Journal of Virology, vol. 78 No. 1, pp. 187-196 (Jan. 2004).
Shirai et al., “An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans,” Journal of Virology, vol. 68 No. 5, pp. 3334-3342 (May 1994).
Tan et al., “Strategies for hepatitis C therapeutic intervention: now and next,” Current opinion in pharmacology, vol. 4 No. 5, pp. 465-470 (Oct. 2004).
C. Henderson (publisher), “Hypericin Profile to Potentially Include Hepatitis C and HIV,” AIDS Weekly, Apr. 24, 1995, pp. 7-8.
Batdelger et al., “Open Label Trial of Therapeutic Hepatitis B Vaccine V-5 Immunitor (V5)Delivered by Oral Route ,” Letters in Drug Design & Discovery, vol. 4 No. 8, pp. 540-544 (Dec. 2007).
Batdelger et al., “Open-label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C,” Vaccine, vol. 26 No. 22, pp. 2733-2737 (May 2008).
Pontisso et al., “Coinfection by hepatitis B virus and hepatitis C virus,” Antiviral therapy, vol. 3 Supplement 3, pp. 137-142 (1998—Abstract only).
Lelie et al., Journal of Medical Virology, vol. 23, pp. 297-301 (1987).
Eisenthal et al., Viral Immunology, vol. 11, pp. 137-145 (1998).
Wladman et al., American Journal of the Medical Sciences, vol. 292, pp. 367-371 (1986).
Avtushenko et al., Journal of Biotechnology, vol. 44, p. 21-28 (1996).
Moldoveanu et al, Journal of Infectious Diseases, vol. 167, pp. 84-90 (1993).
Definition of “immunogen”, The On-Line Medical Dictionary, cancerweb.ncl.ac.uk/omd/, 2003.
Jirathitikal et al, HIV Cin Trials 2002;3(1): 21-26.
Jirathitikal et al., Electronic Journal of Biotechnology ISSN: 0717-3458, vol. 6, No. 1, Apr. 15, 2003.
Jirathitikal et al., Vaccine 21 (2003) 624-628; Current Pharmaceutical Design, 2003, 9 (18): 1419-1431.
Bourinbaiar et al., Acta virologica 48: 73-78, 2004.
Jirathitikal et al., European Journal of Clinical Nutrition (2004) 58,110-115.
Jirathitikal et al., Journal of Clinical Virology 744 (2004), 1-8.
Bourinbaiar et al., Viral Immunology 16(4), 2003, 427-445.
Epand et al., Biochem. J. (2002) 365, 841-848.
Definition “pill”, Dorland's Illustrated Medical Dictionary, mercksource.com/pp/us/cns—health—library—frame.jsp?pg=/pp/us/cns/cns—hl—dorlands.jsp?pg=/pp/us/common/dorlands/dorl and/dmd—a-b—00.htm&cd=3d, (indexed Aug. 2002).
Katakam et al., J Pharm Sci Jun. 1995; 84(6):713-6 (Abstract only).
Meruelo et al., “Therapeutic Agents wtih Dramatic Antiretroviral Activity and Little Toxicity at Effective Doses: Aromatic Polycyclic Diones Hypercin and Pseudohypericin,”Proceedings of the National Academy of Sciences, USA, vol. 85 No. 14, pp. 5230-5234 (Jul. 1988).
Miller, Alan L, “St. John's Wort (Hypericum perforatum): clinical effects on depression and other conditions,”Alternative Medicine Review, vol. 3 No. 1, pp. 18-26 (Feb. 1998).
Hepatitis C Vaccine Delivered By Inovio Biomedical's Electroporation System Shows Increased T-Cell Responses And Reduced Viral Loads, Study, Medical News Today, Jul. 4, 2008, Article URL: http://www.medicalnewstoday.com/articles/113964.php.
DNA-based Therapeutic Vaccine for Hepatitis C Posts Encouraging Results, Hepatitis Central, Apr. 29, 2009, URL for Article Source: http://www/biologynews.net/archives/2009/04/23/first—evidence—for—dnabased—vaccination—against—chronic—hepatitis—c.html.

Affiliated with

Also associated with

Rating

Viral vaccine composition, process and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Viral vaccine composition, process and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral vaccine composition, process and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4151369